Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma announced encouraging Phase 2 topline results for its NS002 intranasal epinephrine product demonstrating faster and more consistent absorption compared to EpiPen®. The company plans to initiate a pivotal study in Q4 2026 with a potential NDA submission thereafter. Additionally, Nasus is advancing other pipeline candidates (NS003, NS004…